British drugmaker AstraZeneca has sold the European marketing rights for the opioid-induced constipation drug Moventig to ProStrakan, a unit of Japanese biopharma firm Kyowa Hakko Kirin.
It is the second big sale of a non-core drug that the company has made in the last two days.
Source: Fortune
Filed Under: Drug Discovery
